Shots:

• The P-II TANGO study evaluating the safety & efficacy of gosuranemab vs PBO in 654 patients aged 50–80 yrs with MCI due to AD or with mild AD for 78 wks across 97 sites- followed by a dose-blind long term extension period
• The trial did not meet its 1EPs i.e change from baseline on CDR-SB @ 78 wks.- no treatment benefit was observed on exploratory efficacy EPs includes ADAS-Cog 13- ADCS-ADL- MMSE & FAQ. Additionally- the therapy was well-tolerated overall & safety outcomes were consistent with previous studies of gosuranemab
• The company has decided to discontinue the further clinical development of gosuranemab while investigation of additional data include CSF biomarkers are ongoing

  | Ref: Globe Newswire | Image:Biogen